Remarkable response as a new indicator for endoscopic evaluation of local efficacy of non-surgical treatments for esophageal cancer
© 2024. The Author(s) under exclusive licence to The Japan Esophageal Society..
In Japan, standard of care of the patients with resectable esophageal cancer is neoadjuvant chemotherapy (NAC) followed by esophagectomy. Patients unfitted for surgery or with unresectable locally advanced esophageal cancer are generally indicated with definitive chemoradiotherapy (CRT). Local disease control is undoubtful important for the management of patients with esophageal cancer, therefore endoscopic evaluation of local efficacy after non-surgical treatments must be essential. The significant shrink of primary site after NAC has been reported as a good indicator of pathological good response as well as favorable survival outcome after esophagectomy. And patients who could achieve remarkable shrink to T1 level after CRT had favorable outcomes with salvage surgery and could be good candidates for salvage endoscopic treatments. Based on these data, "Japanese Classification of Esophageal Cancer, 12th edition" defined the new endoscopic criteria "remarkable response (RR)", that means significant volume reduction after treatment, with the subjective endoscopic evaluation are proposed. In addition, the finding of local recurrence (LR) at primary site after achieving a CR was also proposed in the latest edition of Japanese Classification of Esophageal Cancer. The findings of LR are also important for detecting candidates for salvage endoscopic treatments at an early timing during surveillance after CRT. The endoscopic evaluation would encourage us to make concrete decisions for further treatment indications, therefore physicians treating patients with esophageal cancer should be well-acquainted with each finding.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Esophagus : official journal of the Japan Esophageal Society - 21(2024), 2 vom: 01. März, Seite 85-94 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yano, Tomonori [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chemoradiotherapy |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 22.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10388-024-01043-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368439380 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368439380 | ||
| 003 | DE-627 | ||
| 005 | 20240323000751.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240214s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10388-024-01043-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM368439380 | ||
| 035 | |a (NLM)38353829 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yano, Tomonori |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Remarkable response as a new indicator for endoscopic evaluation of local efficacy of non-surgical treatments for esophageal cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 22.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s) under exclusive licence to The Japan Esophageal Society. | ||
| 520 | |a In Japan, standard of care of the patients with resectable esophageal cancer is neoadjuvant chemotherapy (NAC) followed by esophagectomy. Patients unfitted for surgery or with unresectable locally advanced esophageal cancer are generally indicated with definitive chemoradiotherapy (CRT). Local disease control is undoubtful important for the management of patients with esophageal cancer, therefore endoscopic evaluation of local efficacy after non-surgical treatments must be essential. The significant shrink of primary site after NAC has been reported as a good indicator of pathological good response as well as favorable survival outcome after esophagectomy. And patients who could achieve remarkable shrink to T1 level after CRT had favorable outcomes with salvage surgery and could be good candidates for salvage endoscopic treatments. Based on these data, "Japanese Classification of Esophageal Cancer, 12th edition" defined the new endoscopic criteria "remarkable response (RR)", that means significant volume reduction after treatment, with the subjective endoscopic evaluation are proposed. In addition, the finding of local recurrence (LR) at primary site after achieving a CR was also proposed in the latest edition of Japanese Classification of Esophageal Cancer. The findings of LR are also important for detecting candidates for salvage endoscopic treatments at an early timing during surveillance after CRT. The endoscopic evaluation would encourage us to make concrete decisions for further treatment indications, therefore physicians treating patients with esophageal cancer should be well-acquainted with each finding | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Chemoradiotherapy | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Endoscopy | |
| 650 | 4 | |a Esophageal cancer | |
| 650 | 4 | |a Local recurrence | |
| 650 | 4 | |a Remarkable response | |
| 700 | 1 | |a Hayashi, Yoshito |e verfasserin |4 aut | |
| 700 | 1 | |a Ishihara, Ryu |e verfasserin |4 aut | |
| 700 | 1 | |a Iijima, Katsunori |e verfasserin |4 aut | |
| 700 | 1 | |a Iwakiri, Katsuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Uesato, Masaya |e verfasserin |4 aut | |
| 700 | 1 | |a Oyama, Tsuneo |e verfasserin |4 aut | |
| 700 | 1 | |a Katada, Chikatoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kawada, Kenro |e verfasserin |4 aut | |
| 700 | 1 | |a Kushima, Ryoji |e verfasserin |4 aut | |
| 700 | 1 | |a Tateishi, Yoko |e verfasserin |4 aut | |
| 700 | 1 | |a Fujii, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Manabe, Noriaki |e verfasserin |4 aut | |
| 700 | 1 | |a Minami, Hitomi |e verfasserin |4 aut | |
| 700 | 1 | |a Kawakubo, Hirofumi |e verfasserin |4 aut | |
| 700 | 1 | |a Tsubosa, Yasuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Sachiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kadota, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Minashi, Keiko |e verfasserin |4 aut | |
| 700 | 1 | |a Takeuchi, Hiroya |e verfasserin |4 aut | |
| 700 | 1 | |a Doki, Yuichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Muto, Manabu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Esophagus : official journal of the Japan Esophageal Society |d 2011 |g 21(2024), 2 vom: 01. März, Seite 85-94 |w (DE-627)NLM217523269 |x 1612-9067 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2024 |g number:2 |g day:01 |g month:03 |g pages:85-94 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10388-024-01043-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2024 |e 2 |b 01 |c 03 |h 85-94 | ||